Current therapeutic options for treatment of dyslipidemia, primarily, are limited to "statins". Statins have proven to have extensive cardiovascular benefits for both primary and secondary prevention of major cardio-and cerebrovascular disease (CVD) events. These benefits arise not only from the lipid lowering effects of the statins but also because of their multiple pleiotropic effects. Conventional drugs like fibrates, nicotinic acid, bile acid sequesterants have failed to show meaningful clinical benefits secondary to an increase in the high-density lipoprotein (HDL) cholesterol (HDL-C) or reduction of triglycerides. Also, targeting HDL and non-HDL cholesterol levels has not found a place in the recent guidelines due to absence of any significant clinical benefit. However, patients in whom additional reductions in LDL cholesterol is sought after, are those where the newer agents-ezetemibe, PCSK9 inhibitors and a multitude of options are being studied.
This chapter focuses on the newer non-statin medications (also excluding fibrates, niacin, bile acid sequesterants) available for reduction in low-density lipoprotein (LDL) cholesterol (LDL-C) as well as emerging therapies for increase of HDL cholesterol, reduction of triglycerides, and reduction of lipoprotein (a).
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REDUCTION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
Despite the availability of statins, there remains an intense interest in the development of new LDL lowering agents (Table 1) ; some agents have been already approved and others are still in clinical development. Among all the drugs listed in Table 1 , the most exciting and promising class are the cholesterol absorption inhibitors and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Cholesterol Absorption Inhibitors
Mechanism of Action
Ezetimibe is the first lipid-lowering drug that inhibits intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients. By inhibiting cholesterol absorption at the level of the brush border of the intestine [by interaction with the NiemannPick C1-like protein 1 (NPC1L1)], ezetimibe reduces the amount of cholesterol delivered to the liver. In response to reduced cholesterol delivery, the liver reacts by upregulating LDL receptor expression, which in turn leads to increased clearance of LDL-C from the blood.
Efficacy in Clinical Studies
In clinical studies, ezetimibe in monotherapy reduces LDL-C in hypercholesterolemic patients by 15-22%. Combined therapy with ezetimibe and a statin provides an incremental reduction in LDL-C levels of 15-20%. In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) ezetimibe was added to simvastatin (40 mg) in patients after ACS. A total of 18 144 patients were randomized; 170 fewer events (32.7 vs. 34.7%) were recorded in the group taking simvastatin plus ezetimibe (p = 0.016). Also, ischemic stroke was reduced by 21% in this trial (p = 0.008). There was no evidence of harm caused by the further LDL-C reduction. IMPROVE-
•
IT supports the proposal that ezetimibe should be used as second-line therapy in association with statins when the therapeutic goal is not achieved at the maximal tolerated statin dose or in patients intolerant of statins or with contraindications to these drugs. Such a recommendation has been endorsed in the recent ACC/AHA 2013 and ESC 2016 guidelines as well.
Adverse Effects and Interactions
The recommended dose of ezetimibe of 10 mg/day can be administered in the morning or evening without regard to food intake. There are no clinically significant effects of age, sex or race on ezetimibe pharmacokinetics, and no dosage adjustment is necessary in patients with mild hepatic impairment or mild to severe renal insufficiency. Ezetimibe can be co-administered with any dose of any statin. No major adverse effects have been reported; the most frequent adverse effects are moderate elevations of liver enzymes and muscle pain.
PCSK9 Inhibitors
Mechanism of Action
Recently a new class of drugs, PCSK9 inhibitors, has become available, that targets a protein (PCSK9) involved in the control of the LDL receptors (LDL-R) on the hepatocytes. Since interaction of "PCSK9-LDL R" triggers the intracellular degradation of the LDL-R, lower levels of circulating PCSK9 will result in a higher expression of LDL-Rs at the cell surface and therefore in a reduction of circulating LDL-C levels. The mechanism of action of the therapeutic strategies relate to the reduction of plasma levels of PCSK9, which in turn is not available to bind the LDL-R. Several therapeutic approaches to the inhibition of PCSK9 have been proposed:
• The development of two antisense oligonucleotides (ASOs) against intracellular PCSK9 was stopped in phase I due to safety concerns.
• In a phase I trial, siRNA inhibitor of PCSK9, showed a dose-dependent reduction in LDL-C, with a 40% reduction with the highest dose. The durability of the effect on LDL-C and PCSK9 levels needs to be confirmed in larger studies, and this agent will enter in phase II.
• Inhibition of PCSK9 binding to LDL receptor by adnectins are in phase I.
• A peptide based anti-PCSK9 vaccine is being studied to provide a long-term LDL-C reduction.
• Finally, monoclonal antibodies (mAbs) against PCSK9 are the most extensively studied, with two mAbs approved in 2015-alirocumab and evolocumab, and two other with published phase II data, bococizumab and LY3015014.
Efficacy of mAbs in Clinical Studies
In combination with a statin or in monotherapy, mAbs induce dramatic and significant decreases in LDL-C (from 45% to 70%) and in all the other atherogenic parameters non-HDL-C, apolipoprotein (apo) B, and also lipoprotein(a) [Lp (a)]. Three large phase III programs have been developed with alirocumab, evolocumab, and bococizumab administered as SC injections every 2 weeks or every 4 weeks. So far, the efficacy has been demonstrated:
• In patients with heterozygous and homozygous familial hypercholesterolemia (FH) • In high-risk patients not controlled by maximally tolerated statin therapy Encouraging findings suggesting that PCSK9 mAbs can decrease cardiovascular (CV) events have been observed from exploratory or post-hoc analysis as part of the longer term safety trials ODYSSEY LONG TERM with alirocumab and OSLER with evolocumab. Moreover, meta-analyses of phase II and III trials found reduced total mortality with alirocumab and evolocumab, in trials ranging from 12 to 78 weeks, with several limitations in these analyses, particularly due to the limited number of either CV events or deaths. Whether PCSK9 mAbs definitively reduce the incidence of CV events in patients on statin therapy shall be demonstrated with the four ongoing CV outcome trials including more than 70,000 high-risk patients.
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PCSK9 inhibition may become a major breakthrough in prevention of CVD. Results of ongoing outcomes studies shall be crucial to evaluate the cost-effectiveness of PCSK9 inhibitor treatment.
Adverse Effects and Interactions
Anti-PCSK9 mAbs are injected subcutaneously, usually every other week, at doses up to 150 mg. The potential for interaction with orally absorbed drugs is absent, as they will not interfere with pharmacokinetics or pharmacodynamics. Anti-PCSK9 mAbs do not modulate pathways involved in biotransformation or drug uptake/ extrusion from cells. To date, alirocumab and evolocumab subcutaneous (SC) injections appeared well-tolerated in trials up to 78 weeks in duration. Injection site reactions were relatively rare and mild. Neurocognitive events were reported more frequently with both alirocumab in ODYSSEY LONG TERM (1.2 vs 0.5%) and evolocumab in OSLER-1 and OSLER-2 (0.9 vs 0.3%). The possibility that PCSK9 inhibitors may induce neurocognitive disorders is evaluated by the ongoing EBBINGHAUS trial. No excess of adverse events has emerged in patients even with LDL-C <25 mg/dL.
Mipomersen
Mipomersen is an antisense oligonucleotide (ASO) that specifically blocks the messenger RNA (mRNA) translation into apoB and thereby the synthesis of apoB-containing lipoproteins. Mipomersen, 200 mg in SC injections once weekly, decreases LDL-C, apoB, and Lp (a) by 25-35% in patients with severe hypercholesterolemia, including heterozygous and homozygous FH. However, side effects are frequent and are related to either injection site reactions and flu-like symptoms, or hepatic fat accumulation and transaminases elevations. The drug has been approved by the FDA with a box warning, only for homozygous FH. However, the dug has not been approved by the EMA due to side effects.
Lomitapide
Microsomal triglyceride transfer protein (MTP) is essential for assembly and secretion of very-low-density lipoproteins (VLDL) in the liver and of chylomicrons in the intestine. Several MTP inhibitors have been tested in humans, most abandoned due to poor gastrointestinal tolerability, elevations in hepatic transaminases and increase of hepatic steatosis. However, lomitapide, an oral MTP inhibitor, has been approved by both FDA and EMA for patients with homozygous FH. In an open label study in 29 homozygous FH patients, lomitapide started at a dose of 5 mg/day and titrated at 4-week intervals to a maximum of 60 mg daily has reduced LDL-C by 50% at week 26 and 38% at week 78. However, despite the LDL-C lowering effect, the poor tolerability and side effects (increases in liver enzymes and hepatic steatosis) should limit the use of lomitapide to negative-negative LDL receptor homozygous FH patients.
Bempedoic Acid
Bempedoic acid (ETC-1002) is an oral agent with a novel dual mechanism of action: by inhibiting ATP citrate lyase, the drug can decrease LDL-C, and by activation of AMP kinase, beneficial effects on glucose, lipids, inflammation, and weight gain could be expected, suggesting a development for patient with hypercholesterolemia and type 2 diabetes. In patients with hypercholesterolemia, ETC-1002 reduced LDL-C levels up to 27% in a phase II trial. In patients with type 2 diabetes, ETC-1002 120 mg/day significantly lowered LDL-C by 43% and high-sensitivity C-reactive protein (hs-CRP) by 41 %. In patients with or without statin intolerance, ETC-1002 lowered LDL-C and hs-CRP more than ezetimibe and the combination of ETC-1002 and ezetimibe induced an additive effect in terms of LDL-C reduction. Larger phase III trials are required to assess long-term efficacy and safety.
Gemcabene
Gemcabene is an oral drug initially evaluated for a broad use in hypercholesterolemia, but with moderate LDL-C lowering effect (up to 25%). The mechanisms of action include an inhibition of acetyl CoA carboxylase and an enhancement of VLDL clearance by decreasing apo CIII. The drug is now planned to be developed for use in homozygous FH based on certain preclinical animal data. effects of torcetrapib arose primarily from off-target toxicity related to activation of the renin-angiotensinaldosterone system (RAAS). The results of the dalcetrapib trial (Dal-OUTCOMES) shows no effects in ACS patients. Phase III trials with anacetrapib (REVEAL) are ongoing.
HDL Infusion Agents
Approaches to promote cholesterol efflux could be the infusion of reconstituted HDL (rHDL) containing ApoA-I and phospholipids. Three rHDL are currently in clinical development MDCO-216 (originally ETC-216), CSL-112, and CER-001 with some published data reporting a positive role on reverse cholesterol transport and carotid atherosclerosis and supporting further clinical investigations.
ApoA-I Upregulators Like ApoA1 Mimetic Peptides
ApoA-I upregulators like apoA1 mimetic peptides, promote cholesterol efflux from tissues by increasing the endogenous production of ApoA-I by stimulating its gene transcription. The oral drug RVX-208 increased Apo-AI and HDL-C levels, and enhanced serum cholesterol efflux capacity. However, in the ASSURE trial, RVX-208 treatment has not been associated with regression of coronary atherosclerosis evaluated by serial intravascular ultrasound imaging. Also, the genetic studies suggesting that low HDL-C is not causative for CVD may cast doubt on the possibilities of these treatment options.
REDUCTION OF TRIGLYCERIDES
Although the CVD risk is increased if fasting triglycerides (TGs) are >150 mg/dL, the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are >200 mg/dL and cannot be lowered by lifestyle measures. The available pharmacological interventions include statins, fibrates, PCSK9 inhibitors and n-3 PUFAs.
New Omega-3 Fatty Acid Preparations
Two new omega-3 fatty acid (FA) formulations have been developed: Vascepa ® containing eicosapentaenoic acid (EPA) ethyl esters and Epanova ® containing free FA formulations of EPA and docosahexaenoic acid (DHA). These two formulations reduced plasma TG by around 30% at a 4 g daily dose. These formulations are currently evaluated in long-term outcome trials, REDUCE-IT for Vascepa ® and STRENGTH for Epanova ® in high cardiovascular risk patients with hypertriglyceridemia on optimal statin therapy.
CAT-2054
CAT-2054, a conjugate of eicosapentaenoic acid and niacin, is a novel inhibitor of the sterol response elementbinding protein (SREBP) transcription factor. CAT-2054 does not activate the GPR109A receptor that causes flushing. In preclinical studies, CAT-2054 reduced plasma LDL-C and PCSK9 in nonhuman primates. A phase I trial has been recently presented, and the drug is planned to enter phase II.
INCREASE OF HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL
The available options for elevating low HDL-C levels are relatively few. While HDL-C levels may be increased by up to 10% by implementing therapeutic lifestyle changes, including weight reduction, exercise, smoking cessation and moderate alcohol consumption, many patients will also require pharmacological intervention if an HDL-C increase is sought. However, until now there has been no clear direct evidence that raising HDL-C really results in CVD prevention. Recent studies aimed at testing this hypothesis have failed to show any beneficial effect [ILLUMINATE (torcetrapib), Dalcetrapib Outcomes (dal-OUTCOMES), ACCELERATE (evacetrapib), HPS2-THRIVE (nicotinic acid plus statin), AIM-HIGH (nicotinic acid on background statin)], although the population selection in the last two studies may not have been optimal. The ongoing study with a cholesteryl ester transfer protein (CETP) inhibitor, the Randomized Evaluation of the Effects of Anacetrapib Through Lipid modification (REVEAL), will provide more information.
Cholesteryl Ester Transfer Protein Inhibitors
To date, the most efficacious pharmacological approach to elevation of low HDL-C levels has involved direct inhibition of CETP by small molecule inhibitors, which may induce an increase in HDL-C by ≥100% on a dosedependent basis. Of the three CETP inhibitors developed originally (torcetrapib, dalcetrapib and anacetrapib), torcetrapib was withdrawn following an excess of mortality in the torcetrapib arm of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. The Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) trial of evacetrapib in acute coronary syndrome subjects on statins was terminated due to futility. Retrospectively, it appears that the deleterious
ApoC3 Antisense Oligonucleotide
An ASO targeted to the Apo C III mRNA in the liver, volanesorsen (formerly ISIS 304801), has been shown to reduce TG levels by 56-86% in three patients with familial chylomicronemia syndrome. This effect was confirmed in a phase II trial conducted in hypertriglyceridemic patients with or without fibrate therapy. Treatment with volanesorsen resulted in dose-dependent decreases in both plasma ApoC3 and triglyceride levels up to 70-80%. Phase III studies are ongoing.
Angiopoietin-like Protein Inhibitors
Angiopoietin-like proteins (ANGPTLs) 3 and 4 are other inhibitors of the activity of lipoprotein lipase. Inhibition of ANGPTLs 3 and 4 using neutralizing mAbs (such as REGN 1500) has been reported to reduce TG levels in animal models. Early human clinical trials are ongoing.
New PPAR-α Agonists
Peroxisome proliferator-activated receptor (PPAR)-α agonists are an old class of drugs known to decrease TG and ApoCIII levels. However, clinical outcome trials have not yielded consistent results. The development of new PPAR-α agonists more potent and selective such as Pemafibrate (K-877) remains of interest. The clinical efficacy of Pemafibrate shall be evaluated in a landmark trial named PROMINENT recently decided. Saroglitazar is the world's first approved dual action PPAR agonist approved for treatment of diabetic dyslipidemia uncontrolled on statin therapy. The oral 4 mg per day dosage reduces TGs by 43.8%, non-HDL by 29.7%, LDL by 18.5% by means of its PPAR-α action and improves insulin sensitivity by means of its PPAR-γ action.
Lipoprotein Lipase Gene Therapy
Alipogene tiparvovec gene therapy has been approved by EMA in 2012. Alipogene tiparvovec is administered through intramuscular injections of an adeno-associated virus vector. This strategy is intended to treat rare patients with LPL deficiency and severe or multiple pancreatitis attacks, despite dietary fat restrictions.
STRATEGIES TARGETING LIPOPROTEIN (A)
The consistent association between elevated Lp(a) levels and increased CVD risk, together with genetic findings, indicates that elevated Lp(a) is a causal risk factor for CVD. By consequence, lowering Lp(a) is a new target in CV prevention.
PCSK9 inhibitors, mipomersen, lomitapide, and CETP inhibitors also decrease Lp(a) usually by around 25-30%, but the clinical significance of this effect is unknown. Highly specific and potent Lp(a) lowering strategy would provide the opportunity to demonstrate that lowering Lp(a) leads to a reduction in CVD.
Antisense Therapy Targeting Lp(a)
ASO ISIS-Apo(a)RX was designed to reduce the synthesis of apo(a) in the liver and consequently to decrease the plasma levels of Lp(a). In a phase I study, SC injections of ISISApo(a) RX (100-300 mg) resulted in dose-dependent, selective reductions of plasma Lp(a) up to 78% in the 300-mg group.
CONCLUSION
Strategies to modify the lipid parameters in a favorable way, are being extensively studied. Of all non-statin therapies, ezetemibe and PCSK9 inhibitors hold promise with their proven clinical efficacy and safety. A number of other drugs with different mechanisms of action are being explored to supplement statins.
